Advertisement

Quality of Life in Dermatology

  • Magda Blessmann Weber
  • Mariele Bevilaqua
  • Rebeca Kollar Vieira da Silva
Chapter

Abstract

Dermatoses may have an important powerful effect on patients’ social, family, and professional life. Besides the objective evaluation of therapeutic results, the influence of diseases on patients’ quality of life, by way of confirmed questionnaires, is also considered relevant, even though the majority of dermatologic patients do not have life-threatening illness but only suffer from the social stigma because of clear evidence of dermatoses. In this context, the formulation of scales measuring the impact of the disease and its treatment is an important reality and helps the physician in the global evaluation of the patient.

Keywords

Quality of life Scales Dermatology Pediatrics Public health 

References

  1. 1.
    Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272(8):619–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622–9.CrossRefPubMedGoogle Scholar
  3. 3.
    The WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;10:1403–9.Google Scholar
  4. 4.
    Weber MB, Mazzotti NG, Prati C, Cestari TF. Quality of life assessment in the overall evaluation of dermatology patients. HCPA. 2006;26(2):35–44.Google Scholar
  5. 5.
    Finlay AY, Khan GK. Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Madhulika A, Aditya K. Psychodermatology: an update. J Am Acad Adermatol. 1996;34:1030–46.CrossRefGoogle Scholar
  7. 7.
    Folks DG, Warnock JK. Psycocutaneous disorders. Curr Psychiatry Rep. 2001;3:219–25.CrossRefPubMedGoogle Scholar
  8. 8.
    Walker C, Papadopoulos L. Psychodermatology: the psychological impact of skin disorders. New York, Cambridge University Press, 2005. JAMA. 2007;297:97–8.Google Scholar
  9. 9.
    Tucker P, et al. The psychosocial impact of alopecia areata. J Health Psychol. 2009;14(1):142–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Manzoni APDS, Weber MB, Nagatomi ARS, Pereira RL, Townsend RZ, Cestari TF. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol. 2013;88:894.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gaspar, Tania et al. Qualidade de vida e bem-estar em crianças e adolescentes. Rev Bras Ter Cogn Dez. 2006;2(2):47–60. ISSN 1808-5687.Google Scholar
  12. 12.
    Chren MM. Measurement of vital signs for skin diseases. J Invest Dermatol. 2005;125(4):viii–x.CrossRefPubMedGoogle Scholar
  13. 13.
    Finlay AY. Quality of life in dermatology: after 125 years, time for more rigorous reporting. Br J Dermatol. 2014;170:4–6. doi: https://doi.org/10.1111/bjd.12737.CrossRefPubMedGoogle Scholar
  14. 14.
    Fleck MPA, Leal OF, Louzada S, et al. Desenvolvimento da versão em português do instrumento de avaliação de qualidade de vida da OMS (WHOQOL-100). Rev Bras Psiquiatr. 1999;21(1):19–28.CrossRefGoogle Scholar
  15. 15.
    Development of the World Health Organization WHOQOL-Bref quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28(3):551–8.Google Scholar
  16. 16.
    Fleck MPA, Louzada S, Xavier M, et al. Aplicação da versão em português do instrumento abreviado de avaliação da qualidade de vida “WHOQOLbref”. Rev Saude Publica. 2000;34(2):178–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136(3):305–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Skoet R, Zachariae R, Agner T. Contact dermatitis and quality of life: a structured review of the literature. Br J Dermatol. 2003;149(3):452–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure. Rev Bras Reumatol. 1999;39(3):143–150., maio-jun.Google Scholar
  21. 21.
    Lindholm C, Bjellerup M, Christensen OB, Zederfeldt B. Quality of life in chronic leg ulcer patients. An assessment according to the Nottingham health profile. Acta Derm Venereol. 1993;73(6):440–3.PubMedGoogle Scholar
  22. 22.
    Teixeira-Salmela LF, Magalhães LC, Souza AC, Lima MC, Lima RCM, Goulart F. Adaptação do Perfil de Saúde de Nottingham: um instrumento simples de avaliação da qualidade de vida. Cad Saude Publica. 2004;20(4):905–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Gilson BS, Gilson JS, Bergner M, et al. The sickness impact profile. Development of an outcome measure of health care. Am J Public Health. 1975;65(12):1304–10.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19(8):787–805.CrossRefPubMedGoogle Scholar
  25. 25.
    Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv. 1976;6(3):393–415.CrossRefPubMedGoogle Scholar
  26. 26.
    Feio ALJ, Batel Marques FJ, Alexandrino BM, Salek MS. Portuguese cultural adaptation and linguistic validation of Sickness Impact Profile (PSIP). Qual Life Res. 1995;4:424–5.Google Scholar
  27. 27.
    Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol. 1990;123(6):751–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Qual Life Res. 1996;5(1):131–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial. Br J Dermatol. 1993;129(4):422–30.CrossRefPubMedGoogle Scholar
  30. 30.
    Ruta DA, Garratt AM, Leng M, Russell IT, MacDonald LM. A new approach to the measurement of quality of life. The patient- generated index. Med Care. 1994;32(11):1109–26.CrossRefPubMedGoogle Scholar
  31. 31.
    Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol. 2000;39(11):801–6.CrossRefPubMedGoogle Scholar
  32. 32.
    De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002;138(9):1221–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, Finlay AY. The children’s dermatology life quality index: validation of the cartoon version. Br J Dermatol. 2003;148(2):285–90.CrossRefPubMedGoogle Scholar
  35. 35.
    Lewis-Jones MS, Finlay AY, Dykes PJ. The infants’ dermatitis quality of life index. Br J Dermatol. 2001;144(1):104–10.CrossRefPubMedGoogle Scholar
  36. 36.
    Hahn HB, Melfi CA, Chuang TY, et al. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol. 2001;45(1):44–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37(1):41–50.CrossRefPubMedGoogle Scholar
  38. 38.
    Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–13.CrossRefPubMedGoogle Scholar
  39. 39.
    Kadyk DL, McCarter K, Achen F, Belsito DV. Quality of life in patients with allergic contact dermatitis. J Am Acad Dermatol. 2003;49(6):1037–48.CrossRefPubMedGoogle Scholar
  40. 40.
    Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol. 1995;133(4):575–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80(6):430–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences Study Group. Sensitivity of the dermatology life quality index to clinical change in patients with psoriasis. Br J Dermatol. 2003;149(2):318–22.CrossRefPubMedGoogle Scholar
  43. 43.
    Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141(4):698–702.CrossRefPubMedGoogle Scholar
  44. 44.
    Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health related quality of life. Int J Dermatol. 2002;41(3):151–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148(2):373–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm Venereol. 2000;80(4):272–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol. 2000;143(5):979–82.CrossRefPubMedGoogle Scholar
  48. 48.
    Ferraz LB, Almeida FA, Vasconcellos MR, Facina AS, Ciconelli RM, Ferraz MB. The impact of lupus erythematosus cutaneous on the quality of life: the Brazilian-Portuguese version of DLQI. Qual Life Res. 2006;15:565–70.CrossRefPubMedGoogle Scholar
  49. 49.
    Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169–80.CrossRefPubMedGoogle Scholar
  50. 50.
    Loo WJ, Diba V, Chawla M, Finlay AY. Dermatology life quality index: influence of an illustrated version. Br J Dermatol. 2003;148(2):279–84.CrossRefPubMedGoogle Scholar
  51. 51.
    Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433–40.CrossRefPubMedGoogle Scholar
  52. 52.
    Paula HR, Haddad A, Weiss MA, Dini GM, Ferreira LM. Translation, cultural adaptation, and validation of the American Skindex-29 quality of life index. An Bras Dermatol. 2014;89(4):600–7.Google Scholar
  53. 53.
    Anderson R, Rajagopalan R. Responsiveness of the Dermatology-specific Quality of Life (DSQL) instrument to treatment for acne vulgaris in a placebo-controlled clinical trial. Qual Life Res. 1998;7(8):723–34.CrossRefPubMedGoogle Scholar
  54. 54.
    Bech P. Quality of life measurement in the medical setting. Eur Psychiatry. 1995;10:83–5.CrossRefGoogle Scholar
  55. 55.
    Loney T. Psychosocial effects of dermatological-related social anxiety in a sample of acne patients. J Health Psychol. 2008;13(1):47–54.CrossRefPubMedGoogle Scholar
  56. 56.
    Capoore HS, et al. Does psychological intervention help chronic skin conditions? Postgrad Med J. 1998;74:662–4.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66(Suppl 1):34–40.CrossRefPubMedGoogle Scholar
  58. 58.
    Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol. 2014;31(3):309–18.Google Scholar
  59. 59.
    Eismann EA, Lucky AW, Cornwall R. Hand function and quality of life in children with epidermolysis bullosa. Pediatr Dermatol. 2014;31(2):176–82.CrossRefPubMedGoogle Scholar
  60. 60.
    Klatchoian DA, et al. Qualidade de vida de crianças e adolescentes de São Paulo: confiabilidade e validade da versão brasileira do questionário genérico Pediatric quality of life inventory TM versão 4.0. J Pediatr. 2008;84(04):308–25.CrossRefGoogle Scholar
  61. 61.
    Scarpelli, Ana C et al. The Pediatric Quality of life inventory™ (PedsQL™) family impact module: reliability and validity of the Brazilian version. Health and Quality of Life Outcomes. 2008;6:35–42.Google Scholar
  62. 62.
    Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126–39.CrossRefPubMedGoogle Scholar
  63. 63.
    Prati C, Comparin C, Boza JC, Cestari TF. Validação para o português falado no Brasil do instrumento Escore da Qualidade de Vida na Dermatologia Infantil (CDLQI). Med Cutan Iber Lat Am. 2010;38:229–33.Google Scholar
  64. 64.
    Manificat S, Dazord A. Évaluation de la qualité de vie de l’enfant: validation d’un questionnaire, premiers résultats. Neuropsychiatr Enfance Adolesc. 1997;45:106–14.Google Scholar
  65. 65.
    Assumpção Jr, Francisco B, Kuczynski E, Sprovieri MH, Aranha EMG. Escala de avaliação de qualidade de vida: (AUQEI – Autoquestionnaire Qualité de Vie Enfant Imagé) validade e confiabilidade de uma escala para qualidade de vida em crianças de 4 a 12 anos. Arq Neuro-Psiquiatr. 2000;58(1):119–27.Google Scholar
  66. 66.
    Weber MB, Lorenzini D, Reinehr CPH, Lovato B. Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras Dermatol. 2012 Oct;87(5):697–702.CrossRefPubMedGoogle Scholar
  67. 67.
    Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1(1):53.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Finlay AY, Kelly SE. Psoriasis – an index of disability. Clin Exp Dermatol. 1987;12(1):8–11.CrossRefPubMedGoogle Scholar
  69. 69.
    Kent G, al Abadie M. The psoriasis disability index – further analyses. Clin Exp Dermatol. 1993;18(5):414–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Gupta MA, Gupta AK. The psoriasis life stress inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75(3):240–3.PubMedGoogle Scholar
  71. 71.
    McKenna SP, Cook SA, Whalley D, et al. Development of the PSORIQoL, a psoriasis specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003;149(2):323–31.CrossRefPubMedGoogle Scholar
  72. 72.
    Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol. 2000;43(2 Pt1):229–33.CrossRefPubMedGoogle Scholar
  74. 74.
    Oakley AM. The acne disability index: usefulness confirmed. Australas J Dermatol. 1996;37(1):37–9.CrossRefPubMedGoogle Scholar
  75. 75.
    Zaraa I, Belghith I, Ben Alaya N, Trojjet S, Mokni M, Ben OA. Severity of acne and its impact on quality of life. Skinmed. 2013;11(3):148–53.PubMedGoogle Scholar
  76. 76.
    Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol. 1989;14(3):194–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992;17(1):1–3.CrossRefPubMedGoogle Scholar
  78. 78.
    Gupta A, Sharma YK, Dash KN, Chaudhari ND, Jethani S. Quality of life in acne vulgaris: relationship to clinical severity and demographic data. Indian J Dermatol Venereol Leprol. 2016;82(3):292–7.Google Scholar
  79. 79.
    Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne – assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001;26(5):380–5.CrossRefPubMedGoogle Scholar
  80. 80.
    McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. PharmacoEconomics. 2003;21(15):1069–79.CrossRefPubMedGoogle Scholar
  81. 81.
    Ladbrooke S, Finch C, Fryatt E, Allgar V, Eady A, Layton A. Twenty years on APSEA still hits the spot: validation of the Assessment of the Psychological and Social Effects of Acne (APSEA) questionnaire in a large cohort of patients with acne. Br J Dermatol. 2015;173(Suppl. S1):21–76.Google Scholar
  82. 82.
    Fehnel SE, McLeod LD, Brandman J, et al. Responsiveness of the Acne-Specific Quality of Life Questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res. 2002;11(8):809–16.CrossRefPubMedGoogle Scholar
  83. 83.
    Kent G, al-Abadie M. Factors affecting responses on dermatology life quality index items among vitiligo sufferers. Clin Exp Dermatol. 1996;21(5):330–3.CrossRefPubMedGoogle Scholar
  84. 84.
    Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149(3):572–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Lieu TJ, Pandya AG. Melasma quality of life measures. Dermatol Clin. 2012;30(2):269–280., viii. doi: https://doi.org/10.1016/j.det.2011.11.009.CrossRefPubMedGoogle Scholar
  86. 86.
    Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida ART, Rêgo VRPA, Mendes AMD, Filho JWA, Junqueira H. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006;156:13–20.CrossRefPubMedGoogle Scholar
  87. 87.
    Wallenhammar LM, Nyfjall M, Lindberg M, Meding B. Health-related quality of life and hand eczema – a comparison of two instruments, including factor analysis. J Invest Dermatol. 2004;122(6):1381–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Zampieron A, Buja A, Fusco M, Linder D, Bortune M, Piaserico S, Baldo V. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150(3):309–16. Epub 2014 Sep 18PubMedGoogle Scholar
  89. 89.
    Chen SC, Yeung J, Chren MM. Scalpdex: a quality of life instrument for scalp dermatitis. Arch Dermatol. 2002;138(6):803–7.CrossRefPubMedGoogle Scholar
  90. 90.
    Buske-Kirschbaum A, Geiben A, Hellhammer D. Psychobiological aspects of atopic dermatitis: an overview. Psychother Psychosom. 2001;70(1):6–16.CrossRefPubMedGoogle Scholar
  91. 91.
    Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13–4.Google Scholar
  92. 92.
    Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol. 2004;150(2):274–83.CrossRefPubMedGoogle Scholar
  93. 93.
    Eun H, Finlay AY. Measurement of atopic dermatitis disability. Ann Dermatol. 1990;2:9–12.CrossRefGoogle Scholar
  94. 94.
    Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the dermatitis family impact questionnaire. Br J Dermatol. 1998;138:107–13.CrossRefPubMedGoogle Scholar
  95. 95.
    Poindexter G, Monthrope Y, Shah N, Chen S. Pruritus quality of life instrument. J Am Acad Dermatol. 2005;52(3 Suppl 1):P106.Google Scholar
  96. 96.
    Shah N, Palubin K, Lucero M, Chen S. Measuring quality of life impact in patients with pruritus. J Am Acad Dermatol. 2005;52(3 Suppl 1):P105.Google Scholar
  97. 97.
    Love EM, Marrazzo GA, Kini S, Veledar E, Chen SC. ItchyQoL bands: pilot clinical interpretation of scores. Acta Derm Venereol. 2015;95(1):114–5.CrossRefPubMedGoogle Scholar
  98. 98.
    Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P. The PedsQLTM family impact module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55. doi: https://doi.org/10.1186/1477-7525-2-55.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Scarpelli AC, Paiva SM, Pordeus IA, Varni JW, Viegas CM, Allison PJ. The Pediatric Quality of Life InventoryTM (PedsQLTM) family impact module: reliability and validity of the Brazilian version. Health Qual Life Outcomes. 2008;6:35. doi: https://doi.org/10.1186/1477-7525-6-35.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Basra MKA, Sue-Ho R, Finlay AY. Family dermatology life quality index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156:528–38. Erratum: Br J Dermatol. 2007;156:791.Google Scholar
  101. 101.
    Weber MB, Fontes Neto PT, Prati C, Soirefman M, Mazzotti NG, Barzenski B, et al. Improvement of pruritus and quality of life of children with atopic dermatitis and their families after joining support groups. JEADV. 2008;22:992–9.PubMedGoogle Scholar
  102. 102.
    Dodington SR, Basra MK, Finlay AY, Salek MS. The dermatitis family impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol. 2013;169(1):31–46.CrossRefPubMedGoogle Scholar
  103. 103.
    McKenna SP, Whalley D, Dewar AL, Erdman RA, Kohlmann T, Niero M, Baró E, Cook SA, Crickx B, Frech F, van Assche D. International development of the Parents’ Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res. 2005;14(1):231–41.CrossRefPubMedGoogle Scholar
  104. 104.
    Chamlin SL, Cella D, Frieden IJ, Williams ML, Mancini AJ, Lai JS, Chren MM. Development of the childhood atopic dermatitis impact scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J Invest Dermatol. 2005;125:1106–11.CrossRefPubMedGoogle Scholar
  105. 105.
    Eghlileb AM, Basra MKA, Finlay AY. The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis. Dermatology. 2009;219:63–70.CrossRefPubMedGoogle Scholar
  106. 106.
    Catucci BJ, Basra Mohammad KA, Caminha VR, Rosa CR, Blessmann WM, Ferreira CT. Traducao e validacao do instrumento indice de qualidade de vida para familiares de pacientes com psoriase para o portugues falado no Brasil. An Bras Dermatol. 2013;88(3):488–9.Google Scholar
  107. 107.
    Lewis-Jones MS, Dawe RS, Lowe JG. Quality of life in children with type 1 latex allergy and their parents: use and primary validation of the QoLLAC and QoLLA-P questionnaires. Br J Dermatol. 2005;153(Suppl 1):83–4.Google Scholar
  108. 108.
    Boza JC, Kundu RV, Fabbrin A, Horn R, Giongo N, Cestari TF. Tradução, adaptação cultural e validação do instrumento de avaliação da qualidade de vida de pacientes com vitiligo (VitiQol) para o Português falado no Brasil. An Bras Dermatol. 2015;90(3):355–60.CrossRefGoogle Scholar
  109. 109.
    Alvarenga Tassiana MM, Caldeira Antônio P. Qualidade de vida em pacientes pediátricos com dermatite atópica. J Pediatr. 2009;85(5):415–20.Google Scholar
  110. 110.
    Şenol A, Yücelten AD, Ay P. Development of a quality of life scale for vitiligo. Dermatology. 2013;226(2):185–90. doi: https://doi.org/10.1159/000348466. Epub 2013 May 28CrossRefPubMedGoogle Scholar
  111. 111.
    Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11–8. doi: https://doi.org/10.1016/j.jaad.2012.01.038. Epub 2012 Feb 25CrossRefPubMedGoogle Scholar
  112. 112.
    Gupta V, Sreenivas V, Mehta M, Khaitan BK, Ramam M. Measurement properties of the vitiligo impact scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. Br J Dermatol. 2014;171:1084–90.CrossRefPubMedGoogle Scholar
  113. 113.
    Cardiff’s Department of Dermatology [homepage]. Quality of life questionnaires. Available in: http://sites.cardiff.ac.uk/dermatology/quality-of-life/.

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  • Magda Blessmann Weber
    • 1
  • Mariele Bevilaqua
    • 1
  • Rebeca Kollar Vieira da Silva
    • 1
  1. 1.Dermatology Service of Federal University of Health Sciences of Porto AlegrePorto AlegreBrazil

Personalised recommendations